Allgenesis Receives Notice of Grant of Patent for Fusion Protein of VEGF Trap and Disintegrin in China

Allgenesis Biotherapeutics Inc. – U.S. Patent Granted for Fusion Protein of VEGF Trap and Disintegrin
2021-11-25
Allgenesis Announces FDA Clearance of the IND for AG-73305 for the Treatment of Diabetic Macular Edema
2022-03-31
Show all

February 28th, 2022

Allgenesis Biotherapeutics Inc announced today that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Grant for a Patent covering Allgenesis’ biologic product, AG-73305, a first-in-class drug being developed for retinal diseases. The granted patent provides coverage of the fusion protein and its use to treat angiogenic diseases in the field of ophthalmology, such as nAMD, DME and various retinal diseases in China up to 2036.

“The patent grant in China adds to our goal to cover major global markets for AG-73305,” said Dr. Madhu Cherukury, Chief Executive Officer of Allgenesis. Previously, Allgenesis announced a licensing agreement in September 2021 with AffaMed Therapeutics for the development of AG-73305 for the Greater China markets.  “2022 is setting up to be a tremendous year for Allgenesis, as we continue to progress further towards clinical development for this novel biologic.”  

The U.S. IND filing for AG-73305 and the subsequent first patient enrollment for the Phase 2a DME trial in the U.S. are on track for the first half of 2022. For additional information and collaboration opportunities with Allgenesis, please send emails to info@allgenesis.com or jack.chang@allgenesis.com.

About Allgenesis Biotherapeutics Inc.

Allgenesis is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, nAMD, and other retinal diseases such as RVO, AG-86893 for pterygium, and AG-80308 for Dry Eye Disease.

About AG-73305

AG-73305 is a first-in-class molecule specifically designed for the treatment of DME, nAMD, and other retinal diseases such as RVO. AG-73305 is a single fusion protein that simultaneously binds with high potency and specificity to VEGF and integrin targets, which are known to be involved in retinal diseases. AG-73305 has the potential to treat anti-VEGF responders and non-responders.